Therapeutic Areas

Oncology & Hematology

Advance your Novel Oncology Therapies to Approval and Commercial Success

When the complexities of designing and executing cancer trials in a highly competitive market can mean delays in delivering urgently needed treatments to patients, it pays to have a trusted partner by your side. In the past five years, our experienced teams have helped clients with more than 435 oncology and hematology studies, prepared more than 60 INDs/CTAs, and more than 35 US and European regulatory marketing applications.

Our expertise encompasses traditional cancer treatments, devices/diagnostics, and specialized therapies, including vaccines, gene and cell therapies, and immunotherapies.

Developing an oncology or hematology therapy? Let’s Talk.

Clinical Trial & Regulatory Consulting Expertise for Cancers & Blood Disorders

Our expertise allows us to confidently handle the most complex trials and patient populations with the attention and focus needed to navigate the cancer and hematology landscape.

Whatever your challenges are, Veristat provides creative and strategic approaches to inform your decision-making, mitigate trial risks, prove safety and efficacy, and achieve approval success. Our regulatory and clinical development experts are poised to launch your oncology or hematology trial:

Rapidly advance your clinical trial to its next milestone.
Reliably achieve regulatory success with regulatory consulting advice, marketing application support, and regulatory publishing.

Gain trusted strategic advice from scientific experts across all disciplines along the clinical development and commercialization pathway.
Ensure ongoing safety for marked products with Post-Market Pharmacovigilance.

Solid Tumors

Brain
Breast
Gastrointestinal
Lung
Skin
and more...

Rare Cancers

Acute Myeloid Leukemia
Glioblastoma
Hodgkin’s Lymphoma
Multiple Myeloma
Pancreatic
and more...

Blood Diseases

Beta-Thalassemia
Hemophilia
Sickle Cell Anemia
Thrombocytopenia
Wiskott-Aldrich Syndrome
and more...

Case Study: Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges, including slow recruitment, data cleansing post-MSU, and site staffing.